Drug Approvals
Jim Cramer: Panic Has Not Been Contained in This Market
I think, ultimately, the big issue for many will be what happens in the United States if we hear about people who didn't go to China who have come down with the disease.
This Drugmaking Dividend Stock Due for Shot in the Arm
Gilead offers a nearly 4% yield and looks ready to return to growth.
3 Languishing Small-Caps That Should Perk Up in 2020
Stemline Therapeutics, Entercom Communications and Ocular Therapeutix offer reasons to think their shares will perform better in the New Year.
Two Biotech Plays to Consider From the Long Side
Let's review the charts of Allakos and Global Blood Therapeutics.
Putting My Covered Call Strategy to Work With 2 Dinged Biotech Stocks
Sharp drops in Heron Therapeutics and Supernus Pharmaceuticals have presented opportunities to make lemonade out of lemons.
Exhaustion? Not Much Evidence Just Yet
The market may need some rest and consolidation, but that doesn't mean it will produce a lot of downside.
2 Small Biotechs to Put on Your 2020 Radar
Shares of Replimune Group and Eyenovia have swung up and down in 2019 but should be on the rise next year.
2 Biotech Stocks to Check Out After Karuna Therapeutics' Rocket-Like Surge
Like Karuna, Sage Therapeutics and Intra-Cellular Therapies also deal in treatments in the mental health arena.
Differing Post-Earnings Tales of 2 Small-Cap Underachievers
Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.
3 Names Making the Case That Investing in Small Biotech Is Never Dull
Karyopharm Therapeutics and Pieris Pharmaceuticals are climbing this week on positive news, while Supernus Pharmaceuticals takes a hit.